Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358483 | 0.90 | SMN1; SMN2 (0.79) | L3MBTL1SMN1; SMN2MEN1KMT2ATMEM97 | |
| SCHEMBL6543983 | 0.89 | SMN1; SMN2 (0.71) | L3MBTL1SMN1; SMN2MEN1KMT2ATMEM97 | |
| SCHEMBL13763531 | 0.88 | L3MBTL1 (0.80) | L3MBTL1SMN1; SMN2POLBALDH1A1MEN1 | |
| SCHEMBL9489991 | 0.86 | NAMPT (0.70) | SMN1; SMN2MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL4154673 | 0.86 | ALDH1A1 (0.56) | SMN1; SMN2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL9491028 | 0.86 | NAMPT (0.70) | SMN1; SMN2MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL1928910 | 0.83 | ERN1 (0.63) | L3MBTL1SMN1; SMN2POLBALDH1A1THRB | |
| SCHEMBL12443610 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL5020958 | 0.82 | FABP4 (0.62) | L3MBTL1SMN1; SMN2POLBALDH1A1THRB | |
| Hydrochloric Acid SCHEMBL9584249 | 0.82 | MEN1 (0.66) | SMN1; SMN2POLBMEN1KMT2ATMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118771989-A | Method for catalyzing hydrosilation reduction of amide into amine by using tridentate nitrogen ligand manganese complex | 浙江工业大学 | 2024-10-15 | — | — | CN | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| CN-1067215-C | Composition of mouse expelling agent containing amide | SHENYANG CHEMICAL INST MINISTR (CN) | 2001-06-20 | — | — | CN | disclosed |
| US-4683330-A | ANTICOAGULANTS, ANTIULCER AGENTS | THE UPJOHN COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| US-4160095-A | PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| US-4157441-A | PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | L3MBTL1 3806/4885SMN1; SMN2 3865/4885POLB 4046/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | L3MBTL1 3806/4885SMN1; SMN2 3865/4885POLB 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.